Birth Control Recommendations for Women with Family History of Endometrial Cancer
Combined oral contraceptives (COCs) are the recommended birth control method for women with a family history of endometrial cancer, as they provide significant long-term protection against developing this malignancy. 1
Why Combined Oral Contraceptives Are Protective
COCs significantly reduce endometrial cancer risk by approximately 50% in ever-users, with greater protection associated with longer duration of use. 1
Every 5 years of COC use reduces endometrial cancer risk by 24% (relative risk 0.76,95% CI 0.73-0.78), demonstrating a clear dose-response relationship. 2
The protective effect persists for decades after discontinuation—lasting at least 15-30 years after stopping COCs, making this one of the most durable cancer prevention benefits of any medication. 2, 3, 4
Even 12 months of use confers protection, with an age-adjusted relative risk of 0.6 compared to never-users (95% CI 0.3-0.9). 4, 5
Mechanism and Strength of Protection
The protective effect is strongest for endometrioid carcinomas (the most common type), with a relative risk of 0.69 (95% CI 0.66-0.71) for ever-users compared to never-users. 2
Protection applies to all major histologic subtypes of endometrial cancer and all degrees of tumor differentiation and invasiveness. 3, 4
COCs work by opposing unopposed estrogen exposure, which is a major risk factor for endometrial cancer (unopposed estrogen increases risk 10- to 30-fold with 5+ years of use). 1
Clinical Impact
An estimated 400,000 cases of endometrial cancer have been prevented in developed countries over the past 50 years (1965-2014) due to oral contraceptive use, including 200,000 cases in the past decade alone. 2
For women using COCs for 10 years, the absolute risk of endometrial cancer before age 75 decreases from 2.3% to 1.3% in high-income countries. 2
Important Considerations for Family History
Family history alone (without Lynch syndrome) does not contraindicate COCs—in fact, it makes them more beneficial as a chemoprevention strategy. 1
If Lynch syndrome is suspected (autosomal dominant disorder with 40-60% lifetime risk of endometrial cancer), genetic testing should be pursued, but COCs remain appropriate for contraception and cancer risk reduction. 1
Women with Lynch syndrome mutations (MLH1, MSH2, MSH6, or PMS2) particularly benefit from COC use given their markedly elevated baseline risk. 1
Alternative Contraceptive Options
While COCs are preferred for their cancer-protective effects, other options include:
Levonorgestrel-releasing intrauterine devices (LNG-IUD) provide excellent contraception and may offer some endometrial protection through local progestin effects, though evidence for cancer prevention is less robust than for COCs. 1
Long-acting reversible contraception (LARC) methods like IUDs or implants are highly effective for pregnancy prevention but lack the established endometrial cancer risk reduction of COCs. 1
Progestin-only methods (pills, injections, implants) may provide some protection, with progestin-only pills showing marked risk reduction in some studies, though data are more limited than for combined formulations. 3
Methods to Avoid
- Unopposed estrogen-containing methods should be avoided in women concerned about endometrial cancer risk, as estrogen without progestin dramatically increases endometrial cancer risk. 1
Common Pitfalls
Do not assume family history is a contraindication to hormonal contraception—this is a common misconception. The progestin component in COCs actually protects against endometrial cancer. 1
Do not delay COC initiation in appropriate candidates, as the protective effect increases with duration of use and persists long after discontinuation. 2, 3
Screen for Lynch syndrome in women with strong family histories (multiple relatives with endometrial or colorectal cancer, especially if diagnosed young), as this changes surveillance recommendations but not contraceptive choices. 1